Inclusion Criteria:

        PROCUREMENT Inclusion

          -  Any patient, regardless of age* or sex, with measurable EBV-positive Hodgkin's or
             non-Hodgkin's Lymphoma, (regardless of the histological subtype)^ or EBV (associated)-
             T/NK- or B cell lymphoproliferative disease

             * The first 3 patients enrolled will be adults. Patients <18 years of age are eligible
             if those first 3 patients do not experience dose limiting toxicity considered to be
             primarily related to the EBVST or Nivolumab.

             ^ Patients with relapsed or refractory lymphoma who failed or are ineligible for an
             autologous hematopoietic cell transplantation are also eligible for this study.

          -  EBV positive tumor (can be pending)

          -  Weighs at least 12kg

          -  Informed consent explained to, understood by and signed by patient/guardian.
             Patient/guardian given a copy of informed consent.

          -  Life expectancy of greater than 6 weeks.

        TREATMENT Inclusion

        - Any patient, regardless of age* or sex, with measurable EBV-positive Hodgkin's or
        non-Hodgkin's Lymphoma, (regardless of the histological subtype)^ or EBV (associated)-T/NK-
        or B cell lymphoproliferative disease

        * The first 3 patients enrolled will be adults. Patients <18 years of age are eligible if
        those first 3 patients do not experience dose limiting toxicity considered to be primarily
        related to the EBVST or Nivolumab.

        ^ Patients with relapsed or refractory lymphoma who failed or are ineligible for an
        autologous hematopoietic cell transplantation are also eligible for this study.

        And

          -  Hodgkin's lymphoma patients in second relapse or first relapse and refractory to at
             least two lines of salvage chemotherapy including Brentuximab Vedotin or primary
             refractory disease after at least two lines therapy or

          -  Non- Hodgkin's lymphoma patients in first relapse and/or refractory to at least one
             salvage chemotherapy or with primary refractory disease after at least two lines of
             therapy or in second or subsequent relapse or

          -  T/NK- or B lymphoproliferative disease in first relapse and/or refractory to at least
             one salvage chemotherapy or with primary refractory disease after at least two lines
             of therapy or in second or subsequent relapse

          -  EBV positive tumor

          -  Patients with life expectancy >/= 6 weeks.

          -  Patients with bilirubin less than or equal to 3x upper limit of normal

          -  AST less than or equal to 5x upper limit of normal

          -  Hgb more than 8.0 (may be a transfused value).

          -  Patients with a creatinine less than or equal to 2x upper limit of normal for age

          -  Pulse oximetry of more than 90% on room air

          -  Patients should have been off other investigational therapy for 4 weeks prior to entry
             in this study.

          -  Patients with a Karnofsky/Lansky score of >/= 60

          -  Recovered from acute toxic effects of prior chemotherapy at least one week before
             entering the study.

          -  Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 6 months after the study is concluded. The
             male partner should use a condom.

          -  Informed consent explained to, understood and signed by patient/guardian.
             Patient/guardian given a copy of informed consent.

        Exclusion Criteria:

        PROCUREMENT Exclusion

          -  Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)

          -  History of solid organ transplant

        TREATMENT Exclusion

          -  Pregnant or lactating due to unknown effects of this therapy on a fetus or lactation

          -  Severe active intercurrent infection.

          -  Current use of systemic corticosteroids >0.5 mg/kg/day

          -  Currently receiving any investigational agents or radiotherapy within 4 weeks prior to
             entering the study.

          -  Patients with central nervous system involvement.

          -  History of allergic reactions attributed to nivolumab or any other checkpoint
             inhibitors.

          -  Uncontrolled autoimmune disease needing systemic steroids or steroid sparing agents
             except for hypothyroidism or type I diabetes.

          -  History of solid organ transplant

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Lipase more than 70U/ml